Soliqua 100/33 100 U/mL

Soliqua 100/33 is a combination of insulin glargine and lixisenatide, designed for subcutaneous administration. This medication is used to manage blood sugar levels in adults with type 2 diabetes. It offers a convenient solution for those requiring dual-action therapy.

Soliqua 100/33 is primarily used for the management of type 2 diabetes in adults. This medication combines insulin glargine, a long-acting insulin, with lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Together, they help control blood sugar levels by improving insulin production and reducing glucose output from the liver. People often ask, 'What is Soliqua 100/33 used for?' It is typically prescribed for individuals who need both basal insulin and GLP-1 receptor agonist therapy.

Common effects of Soliqua 100/33 may include nausea, vomiting, diarrhea, and injection site reactions. Some users may experience hypoglycemia, or low blood sugar, especially when starting the medication or changing doses. It is important to monitor blood sugar levels regularly while using this medication.

Soliqua 100/33 should be handled with care. Store it in a refrigerator and protect it from light. Always check the solution for particles or discoloration before use. Do not share needles or syringes to prevent infection. Consult a healthcare provider before starting this medication, especially if you have a history of severe gastrointestinal disease or pancreatitis.

Soliqua 100/33 may interact with other medications, including oral hypoglycemic agents, corticosteroids, and certain antidepressants. Alcohol can also affect blood sugar levels and should be consumed with caution. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.